Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)11.51bn
- Net income in JPY1.78bn
- Incorporated2006
- Employees141.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zeria Pharmaceutical Co Ltd | 62.29bn | 5.15bn | 105.97bn | 1.74k | 17.30 | 1.55 | 9.97 | 1.70 | 115.29 | 115.29 | 1,389.74 | 1,286.97 | 0.4942 | 1.46 | 3.94 | 35,860,130.00 | 4.10 | 3.10 | 6.94 | 4.98 | 71.60 | 71.28 | 8.30 | 5.92 | 0.7069 | 7.18 | 0.4848 | 45.87 | 12.84 | -1.70 | 26.03 | 2.25 | -17.52 | 1.81 |
| Shin Nippon Biomedical Laboratories Ltd | 18.75bn | 7.25bn | 106.04bn | 994.00 | 14.63 | 5.03 | 12.50 | 5.65 | 174.04 | 174.04 | 450.47 | 506.15 | 0.454 | 1.86 | 7.20 | 18,866,960.00 | 17.61 | 5.06 | 25.67 | 7.65 | 54.28 | 45.48 | 38.79 | 14.97 | 0.9192 | -- | 0.3797 | 24.13 | 17.46 | 0.5778 | 94.65 | -- | 9.71 | -- |
| TOWA PHARMACEUTICAL CO., LTD | 168.06bn | 12.00bn | 106.84bn | 4.08k | 8.70 | 0.7602 | 4.39 | 0.6358 | 238.37 | 238.37 | 3,339.21 | 2,728.22 | 0.5822 | 1.45 | 3.40 | 41,211,380.00 | 4.16 | 5.91 | 5.81 | 7.85 | 40.82 | 44.12 | 7.14 | 10.22 | 0.7652 | -- | 0.5080 | 16.48 | 6.92 | 14.28 | 14.01 | 23.34 | -8.50 | 12.47 |
| KYORIN Holdings, Inc. | 105.46bn | 5.58bn | 111.38bn | 2.22k | 17.71 | 0.7902 | 11.93 | 1.06 | 97.33 | 97.33 | 1,840.39 | 2,181.68 | 0.6304 | 1.38 | 2.79 | 47,460,850.00 | 3.33 | 3.33 | 4.04 | 4.03 | 46.91 | 51.06 | 5.29 | 5.46 | 2.25 | -- | 0.1443 | 70.59 | 2.56 | -1.77 | -35.86 | -11.65 | 0.338 | -2.16 |
| Kissei Pharmaceutical Co Ltd | 65.03bn | 10.91bn | 129.17bn | 1.83k | 10.54 | 0.5693 | 8.68 | 1.99 | 236.63 | 236.63 | 1,410.19 | 4,379.43 | 0.2619 | 1.75 | 2.96 | 35,574,940.00 | 4.44 | 3.16 | 4.76 | 3.42 | 48.47 | 55.98 | 16.94 | 10.45 | 5.03 | -- | 0.008 | 34.12 | -5.31 | -1.83 | 144.48 | 10.83 | -5.39 | 4.01 |
| Mochida Pharmaceutical Co., Ltd. | 110.51bn | 11.07bn | 132.13bn | 1.54k | 11.29 | 0.9504 | 9.63 | 1.20 | 291.39 | 291.39 | 2,913.73 | 3,461.72 | 0.6809 | 2.27 | 3.60 | 71,573,180.00 | 6.82 | 5.22 | 8.25 | 6.40 | 54.16 | 51.57 | 10.02 | 7.76 | 3.58 | -- | 0.00 | 40.56 | 6.98 | 2.51 | 23.08 | 4.39 | 21.99 | 3.04 |
| Sosei Group Corporation | 17.05bn | -224.00m | 144.35bn | 198.00 | -- | 2.56 | 134.40 | 8.47 | -2.73 | -2.73 | 208.57 | 688.04 | 0.1975 | -- | 10.96 | 86,090,910.00 | -0.2596 | -- | -0.2705 | -- | 94.03 | -- | -1.31 | -- | -- | 1.14 | 0.3447 | -- | 100.32 | -- | -31.24 | -- | -- | -- |
| KAKEN PHARMACEUTICAL CO., LTD. | 75.78bn | 9.09bn | 172.50bn | 1.16k | 15.64 | 1.03 | 14.88 | 2.28 | 240.14 | 240.14 | 2,001.90 | 3,646.73 | 0.4614 | 2.11 | 3.69 | 65,101,380.00 | 5.54 | 10.15 | 6.34 | 12.06 | 54.55 | 56.09 | 12.00 | 18.28 | 4.89 | -- | 0.0272 | 37.00 | 1.41 | -5.61 | -28.77 | -15.39 | 6.71 | 0.00 |
| Sawai Group Holdings Co Ltd | 191.56bn | -30.91bn | 175.17bn | 2.97k | -- | 0.8933 | -- | 0.9144 | -706.09 | -706.09 | 4,370.55 | 4,478.04 | 0.5056 | 1.50 | 2.85 | 64,542,120.00 | -11.77 | 1.25 | -16.27 | 1.70 | 33.06 | 38.97 | -23.27 | 2.46 | 1.39 | -140.92 | 0.2669 | 76.82 | 3.52 | 7.92 | -329.08 | -- | 4.38 | 0.00 |
| TAKARA BIO INC. | 66.53bn | 17.73bn | 202.90bn | 1.67k | 11.44 | 2.07 | 9.21 | 3.05 | 147.25 | 147.25 | 552.50 | 815.46 | 0.6302 | 1.17 | 5.21 | 39,933,370.00 | 16.86 | 9.94 | 19.44 | 11.16 | 69.44 | 65.37 | 26.76 | 18.17 | 3.62 | 39.33 | 0.00 | 21.03 | 46.90 | 18.17 | 107.91 | 71.14 | 52.57 | 52.51 |
| Peptidream Inc | 11.51bn | 1.78bn | 208.80bn | 141.00 | 117.18 | 8.43 | 73.16 | 18.14 | 13.71 | 13.71 | 88.66 | 190.55 | 0.3023 | 2.97 | 4.15 | -- | 4.67 | -- | 5.24 | -- | 61.41 | -- | 15.46 | -- | 2.08 | -- | 0.4666 | -- | -19.79 | -- | -18.93 | -- | -- | -- |
| Tsumura & Co | 132.19bn | 20.08bn | 230.66bn | 3.92k | 11.45 | 0.9222 | 7.61 | 1.74 | 262.45 | 262.45 | 1,727.84 | 3,258.35 | 0.3834 | 0.7124 | 2.43 | 33,713,850.00 | 6.04 | 5.19 | 7.48 | 6.28 | 51.40 | 55.78 | 15.75 | 12.78 | 3.03 | -- | 0.1559 | 31.45 | 11.28 | 2.42 | 22.85 | 8.57 | 4.99 | 0.00 |
| JCR Pharmaceuticals Co Ltd | 50.88bn | 14.34bn | 264.82bn | 816.00 | 17.69 | 4.98 | 16.26 | 5.21 | 115.46 | 115.46 | 409.53 | 410.13 | 0.6029 | 0.7641 | 4.98 | 62,346,810.00 | 17.01 | 11.47 | 28.71 | 16.27 | 77.85 | 73.58 | 28.21 | 20.62 | 1.17 | -- | 0.262 | 22.46 | 69.79 | 23.08 | 110.49 | 50.75 | 48.86 | 29.46 |
| Hisamitsu Pharmaceutical Co Inc | 118.83bn | 8.93bn | 277.21bn | 2.78k | 29.41 | 1.04 | 20.45 | 2.33 | 110.68 | 110.68 | 1,471.37 | 3,133.61 | 0.3911 | 2.77 | 3.69 | 42,681,390.00 | 3.02 | 5.15 | 3.43 | 5.83 | 57.41 | 61.16 | 7.72 | 11.52 | 4.20 | -- | 0.005 | 44.97 | 4.96 | -3.81 | 4.41 | -13.89 | 5.56 | 0.6061 |
Data as of Sep 30 2022. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
28.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Taiyo Pacific Partners LPas of 29 Aug 2022 | 9.36m | 7.20% |
| JOHCM (Singapore) Pte Ltd.as of 24 Aug 2021 | 5.75m | 4.42% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 31 Mar 2022 | 4.72m | 3.63% |
| Invesco Advisers, Inc.as of 31 Jul 2022 | 3.05m | 2.35% |
| Baillie Gifford & Co.as of 30 Jun 2022 | 3.01m | 2.32% |
| Nomura Asset Management Co., Ltd.as of 31 Aug 2022 | 2.98m | 2.30% |
| The Vanguard Group, Inc.as of 09 Sep 2022 | 2.23m | 1.72% |
| Nikko Asset Management Co., Ltd.as of 31 Mar 2022 | 2.01m | 1.55% |
| Alma Capital Investment Management SA (UK)as of 30 Jun 2022 | 1.95m | 1.50% |
| BlackRock Fund Advisorsas of 30 Nov 2021 | 1.82m | 1.40% |
More ▼
Data from 30 Sep 2019 - 29 Aug 2022Source: FactSet Research Systems Inc.
